KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo ...
Seeking Alpha

Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025

Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with ...
Seeking Alpha

KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA ® (finerenone) significantly reduced urine ...
Medscape

Mineralocorticoid Blocker Gets EU Nod for Heart Failure

European regulators have moved to broaden the clinical use of Kerendia (finerenone, Bayer), backing its role in a large and previously underserved heart failure population. At its January meeting, the ...